UBS Remains a Hold on Qantas Airways Limited (QUBSF)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Fromyhr covers the Industrials sector, focusing on stocks such as Brambles , Qube Holdings, and Aurizon Holdings. According to TipRanks, Fromyhr has an average return of 10.6% and a 72.94% success rate on recommended stocks.
In addition to UBS, Qantas Airways Limited also received a Hold from Macquarie's Ian Myles in a report issued yesterday. However, today, Morgan Stanley maintained a Buy rating on Qantas Airways Limited (Other OTC: QUBSF).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
7 minutes ago
- Business Insider
Adaptimmune Therapeutics Stock (ADAP) Rockets 50% on CCO Severance Agreement
Adaptimmune Therapeutics (ADAP) stock rocketed higher on Monday after the clinical-stage biopharmaceutical company reached a severance agreement with former Chief Commercial Officer Cintia Piccina. Under the terms of this agreement, Piccina will receive 12 months of pay, $473,800, in a lump-sum payment. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Piccina will also continue to be able to benefit from the Employee 2016 Share Option Scheme. This will allow her to exercise vested options until January 30, 2032. The former CCO was also permitted a 'period of 12 months from the Separation Date to exercise any other Market Value Options that have vested by the Separation Date.' Piccina was terminated as the CCO of Adaptimmune Therapeutics on August 8, 2025. The reason for this was redundancy. Piccina's severance agreement with the company will go into effect on August 23, 2025. Adaptimmune Therapeutics Stock Movement Today Adaptimmune Therapeutics stock was up 47.23% in pre-market trading on Monday, following an 18.38% fall on Friday. The shares have also decreased 88.98% year-to-date and 94.69% over the past 12 months. Today's news saw heavy trading of ADAP stock, with some 270 million shares traded, compared to a three-month daily average of about 38 million units. Is Adaptimmune Therapeutics Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Adaptimmune Therapeutics is Moderate Sell, based on four Hold and two Sell ratings over the past three months. With that comes an average ADAP stock price target of 35 cents, representing a potential 488.24% upside for the shares.
Business Insider
8 minutes ago
- Business Insider
Who Is TipRanks' All-Star Analyst on Microsoft Stock (MSFT)?
The TipRanks All-star Analyst of the Day title goes to analyst Brent Thill of research firm Jefferies. Remarkably, Thill ranks #241 out of the 9,978 Wall Street analysts tracked by TipRanks. One of the key stocks in his coverage is Microsoft (MSFT), for which he is the Best analyst over a one-year time frame. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Microsoft is a multinational technology company known for its software products, including the Windows operating system and Microsoft Azure cloud computing services. For a thorough assessment of the stock, go to TipRanks' Stock Analysis page. When we look at Thill's recommendation for Microsoft stock, we see that he has had a 97% success rate by holding the stock for one year. Plus, he has earned an average return of 25.90% during that period. On an overall basis, copying Thill's trades and holding them for a year would give you an average return of 13%, with 64% of your trades generating a profit. Not Just MSFT Thill primarily focuses on covering the technology sector in the U.S. market. Importantly, his most profitable rating to date was a Buy on Meta (META), a social media and technology company that owns platforms like Facebook, Instagram, and WhatsApp. The analyst earned a massive 215.9% return on the call between November 09, 2022 and November 09, 2023. Following phenomenally successful analysts' ratings can add profit to your portfolio. Find the best analyst to follow for any stock by scrolling down to the ' Best Analyst Covering ' feature on its Analyst Forecast page. Top Analysts on TipRanks.
Business Insider
42 minutes ago
- Business Insider
Morgans upgrades a2 Milk Company (ACOPF) to a Hold
In a report released today, Belinda Moore from Morgans upgraded a2 Milk Company to a Hold, with a price target of A$8.00. The company's shares closed yesterday at $5.25. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Moore is a 4-star analyst with an average return of 7.3% and a 61.29% success rate. Moore covers the Consumer Defensive sector, focusing on stocks such as Treasury Wine Estates Limited, a2 Milk Company, and Elders Limited. In addition to Morgans, a2 Milk Company also received a Hold from Bell Potter's Jonathan Snape in a report issued yesterday. However, on the same day, UBS maintained a Buy rating on a2 Milk Company (Other OTC: ACOPF). The company has a one-year high of $5.87 and a one-year low of $2.90. Currently, a2 Milk Company has an average volume of 887.
